卷 25, 编号 3 (2023) |
CLINICAL ONCOLOGY |
Efficacy and safety of nurulimab+prolgolimab with continued prolgolimab therapy compared to prolgolimab alone as first-line therapy in patients with unresectable or metastatic melanoma: final results of the phase II OBERTON clinical study |
(Rus)
|